ArticleHuman vaccines & immunotherapeutics2024
A prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the recombinant zoster vaccine in Chinese adults ≥50 years of age.
Xinghuo Pang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.